We are live on ! Find out more
BCM

Burrage Capital Management Portfolio holdings

AUM $99.7M
1-Year Est. Return 66.05%
This Fund
S&P 500
This Quarter Est. Return
+15.05%
1 Year Est. Return
+66.05%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$99.7M
AUM Growth
-$23.7M
Cap. Flow
-$26.3M
Cap. Flow %
-26.37%
Top 10 Hldgs %
70.67%
Holding
30
New
3
Increased
3
Reduced
2
Closed
8

Top Buys

1
FOLD
Amicus Therapeutics
FOLD
+$4.88M
2
VSTM icon
Verastem
VSTM
+$2.45M
3
EPZM
Epizyme, Inc
EPZM
+$2.3M
4
RVMD icon
Revolution Medicines
RVMD
+$1.75M
5
INZY
Inozyme Pharma
INZY
+$1.27M

Top Sells

1
PLX icon
Protalix BioTherapeutics
PLX
+$9.48M
2
PTCT icon
PTC Therapeutics
PTCT
+$7.59M
3
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$5.17M
4
TVRD
Tvardi Therapeutics
TVRD
+$3.91M
5
FULC icon
Fulcrum Therapeutics
FULC
+$3.77M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCRX icon
1
BioCryst Pharmaceuticals
BCRX
$2.36B
$13.7M 13.71%
864,916
– –
NTLA icon
2
Intellia Therapeutics
NTLA
$1.59B
$10.3M 10.33%
63,634
– –
EPZM
3
DELISTED
Epizyme, Inc
EPZM
$6.95M 6.97%
836,802
+272,247
+48% +$2.3M
EPIX
4
DELISTED
ESSA Pharma
EPIX
$6.78M 6.8%
237,442
– –
NEO icon
5
NeoGenomics
NEO
$1.9B
$6.68M 6.7%
147,921
– –
LITS
6
Lite Strategy Inc
LITS
$33.6M
$6.64M 6.66%
116,566
– –
CRNX icon
7
Crinetics Pharmaceuticals
CRNX
$8.88B
$5.55M 5.57%
294,620
+22,227
+8% +$391K
CYTK icon
8
Cytokinetics
CYTK
$10.9B
$4.84M 4.85%
244,673
– –
FOLD
9
DELISTED
Amicus Therapeutics
FOLD
$4.82M 4.83%
+500,000
New +$4.88M
HRMY icon
10
Harmony Biosciences
HRMY
$1.96B
$4.23M 4.25%
150,000
– –
INZY
11
DELISTED
Inozyme Pharma
INZY
$4.13M 4.14%
242,517
+73,044
+43% +$1.27M
YMAB
12
DELISTED
Y-mAbs Therapeutics
YMAB
$3.87M 3.88%
114,454
– –
MIRM icon
13
Mirum Pharmaceuticals
MIRM
$7.25B
$3.56M 3.57%
205,866
– –
ADCT icon
14
ADC Therapeutics
ADCT
$172M
$3.04M 3.05%
124,875
– –
VSTM icon
15
Verastem
VSTM
$530M
$2.87M 2.88%
+58,799
New +$2.45M
MRUS
16
DELISTED
Merus
MRUS
$2.75M 2.76%
130,683
– –
GERN icon
17
Geron
GERN
$924M
$2.7M 2.7%
1,912,673
– –
TECX
18
Tectonic Therapeutic
TECX
$615M
$2.18M 2.18%
20,410
– –
RVMD icon
19
Revolution Medicines
RVMD
$39.6B
$1.59M 1.59%
+50,000
New +$1.75M
BDTX icon
20
Black Diamond Therapeutics
BDTX
$103M
$1.35M 1.35%
110,447
– –
GTHX
21
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$1.05M 1.05%
47,708
-70,000
-59% -$1.55M
TPTX
22
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$169K 0.17%
2,164
-70,000
-97% -$5.17M
APLS
23
DELISTED
Apellis Pharmaceuticals
APLS
– –
-80,727
Closed -$3.46M
FULC icon
24
Fulcrum Therapeutics
FULC
$243M
– –
-319,819
Closed -$3.77M
NTLA icon
25
PUT
Intellia Therapeutics
NTLA
$1.59B
– –
-630
Closed -$46K
1
2

Similar funds

WCM
Weld Capital Management New York $98.8M AUM 52.83% 1-Year Est. Return
CCM
Coe Capital Management Highland Park, Illinois $106M AUM 53.24% 1-Year Est. Return
RGM
ROAM Global Management New York $117M AUM
TCM
Taal Capital Management Boston, Massachusetts $122M AUM 50.45% 1-Year Est. Return
RC
Regents Capital Hong Kong $76.8M AUM
AC
Aperimus Capital Marina Del Rey, California $62.2M AUM 47.35% 1-Year Est. Return
QVT
Quantitative Value Technologies Overland Park, Kansas $60.7M AUM
WFWM
Wechter Feldman Wealth Management Parsippany, New Jersey $143M AUM 25.17% 1-Year Est. Return

Burrage Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Burrage Capital Management held 30 positions worth $99.7M, down 19% from $123M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Burrage Capital Management withdrew a net $26.3M in Q2 2021, closing 8 positions and reducing 2 holdings. Its most notable exit was Protalix BioTherapeutics, an estimated $9.48M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, Burrage Capital Management opened a new position in Amicus Therapeutics worth $4.82M.

  • Burrage Capital Management's largest Q2 2021 buy was Amicus Therapeutics: 500,000 shares worth $4.82M.
  • Burrage Capital Management added most to Epizyme, Inc in Q2 2021, an estimated $2.3M increase.
  • Burrage Capital Management's biggest Q2 2021 reduction was Turning Point Therapeutics, Inc. Common Stock, cutting an estimated $5.17M.
  • Burrage Capital Management fully exited Protalix BioTherapeutics in Q2 2021, selling an estimated $9.48M.
  • Burrage Capital Management's ten largest holdings make up 71% of its $99.7M portfolio in Q2 2021.
  • Burrage Capital Management opened 3 new positions and closed 8 in Q2 2021.
  • Burrage Capital Management's portfolio value fell 19% quarter-over-quarter to $99.7M.

Based on Burrage Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.